US study shows that tofacitinib is an efficacious treatment for active RA
Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response (a 20 percent ...
May 25, 2011
0
0